Brought to you by 
Novartis, HGS end late-stage hepatitis C deal
09 Nov 2010
Executive Summary
Novartis has licensed exclusive worldwide rights to Human Genome Sciences' Albuferon (albumin-interferon alpha 2b), a Phase II candidate for chronic hepatitis C. The companies will co-promote Albuferon in the US, sharing commercialization costs in this territory; Novartis pays commercialization fees in all other areas.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com